Glutathione and glutathione peroxidase expression in breast cancer: An immunohistochemical and molecular study

Nenhuma Miniatura disponível

Data

2013-09-01

Autores

Jardim, Bruna Victorasso [UNESP]
Moschetta, Marina Gobbe
Leonel, Camila [UNESP]
Gelaleti, Gabriela Bottaro [UNESP]
Regiani, Vitor Rafael
Ferreira, Livia Carvalho [UNESP]
Lopes, Juliana Ramos [UNESP]
De Campos Zuccari, Debora Ap. Pires

Título da Revista

ISSN da Revista

Título de Volume

Editor

Resumo

The use of prognostic markers for breast cancer allows therapeutic strategies to be defined more efficiently. The expression of glutathione (GSH) and glutathione peroxidase (GPX) in tumor cells has been evaluated as a predictor of prognosis and response to cytotoxic treatments. Its immunoexpression was assessed in 63 women diagnosed with invasive ductal carcinoma in a retrospective study. The results showed that high GSH expression was associated with tumors negative for the estrogen receptor (ER) (P<0.05), and GPX expression was associated with tumors negative for the progesterone receptor (PR) and patient mortality. Focusing on the 37 patients who received adjuvant chemotherapy/radiotherapy (Group I), high expression of GPX was associated with a high rate of patient mortality (P<0.05). The 19 patients who received only adjuvant chemotherapy (Group II) showed high expression of GSH in relation to metastasis (P<0.05). In addition, high levels of GPX expression were significantly associated with a shorter overall survival (P<0.05). To confirm this, the expression of precursor genes of GSH [glutamate cysteine ligase (GCLC) and glutathione synthetase (GSS)] and the GPX gene was analyzed using quantitative PCR in cultured neoplastic mammary cells treated with doxorubicin. Doxorubicin treatment was able to eliminate tumor cells without alterations in the gene expression of GSS, but led to underexpression of the GCLC and GPX genes. Our results suggest that high levels of GPX may be related to the development of resistance to chemotherapy in these tumors, response to treatment and the clinical course of the breast cancer patients.

Descrição

Palavras-chave

Chemotherapy, Glutathione, Immunohistochemistry, Prognosis, Real-time PCR, antineoplastic agent, cyclophosphamide, doxorubicin, epirubicin, estrogen receptor, fluorouracil, glutamate cysteine ligase, glutathione, glutathione peroxidase, glutathione synthase, progesterone receptor, adult, aged, antineoplastic activity, breast carcinoma, cancer adjuvant therapy, cancer cell culture, cancer mortality, cancer radiotherapy, controlled study, female, gene expression, histopathology, human, human cell, human tissue, immunohistochemistry, major clinical study, mastectomy, metastasis, overall survival, priority journal, protein expression, retrospective study, segmental mastectomy

Como citar

Oncology Reports, v. 30, n. 3, p. 1119-1128, 2013.